[go: up one dir, main page]

DK3445351T3 - Acetyl-leucin eller et farmaceutisk acceptabelt salt deraf til forbedret mobilitet - Google Patents

Acetyl-leucin eller et farmaceutisk acceptabelt salt deraf til forbedret mobilitet Download PDF

Info

Publication number
DK3445351T3
DK3445351T3 DK17719692.0T DK17719692T DK3445351T3 DK 3445351 T3 DK3445351 T3 DK 3445351T3 DK 17719692 T DK17719692 T DK 17719692T DK 3445351 T3 DK3445351 T3 DK 3445351T3
Authority
DK
Denmark
Prior art keywords
leucine
acetyl
pharmaceutically acceptable
acceptable salt
improved mobility
Prior art date
Application number
DK17719692.0T
Other languages
English (en)
Inventor
Mallory Factor
Michael Strupp
Original Assignee
Intrabio Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intrabio Ltd filed Critical Intrabio Ltd
Application granted granted Critical
Publication of DK3445351T3 publication Critical patent/DK3445351T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
DK17719692.0T 2016-04-19 2017-04-19 Acetyl-leucin eller et farmaceutisk acceptabelt salt deraf til forbedret mobilitet DK3445351T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB201606834 2016-04-19
PCT/GB2017/051090 WO2017182802A1 (en) 2016-04-19 2017-04-19 Acetyl-leucine or a pharmaceutically acceptable salt thereof for improved mobility and cognitive function

Publications (1)

Publication Number Publication Date
DK3445351T3 true DK3445351T3 (da) 2024-11-04

Family

ID=58633040

Family Applications (1)

Application Number Title Priority Date Filing Date
DK17719692.0T DK3445351T3 (da) 2016-04-19 2017-04-19 Acetyl-leucin eller et farmaceutisk acceptabelt salt deraf til forbedret mobilitet

Country Status (27)

Country Link
US (4) US10905670B2 (da)
EP (2) EP4501406A3 (da)
JP (3) JP7387264B2 (da)
KR (4) KR102413754B1 (da)
CN (2) CN109069463B (da)
AU (2) AU2017252507B2 (da)
BR (1) BR112018071547A2 (da)
CA (1) CA3021155A1 (da)
DK (1) DK3445351T3 (da)
ES (1) ES2994242T3 (da)
FI (1) FI3445351T3 (da)
HR (1) HRP20241552T1 (da)
HU (1) HUE069219T2 (da)
IL (3) IL310508A (da)
LT (1) LT3445351T (da)
MD (1) MD3445351T2 (da)
MX (2) MX388461B (da)
NZ (1) NZ747307A (da)
PL (1) PL3445351T3 (da)
PT (1) PT3445351T (da)
RS (1) RS66142B1 (da)
RU (1) RU2745912C2 (da)
SG (2) SG11201809031XA (da)
SI (1) SI3445351T1 (da)
SM (1) SMT202400459T1 (da)
WO (1) WO2017182802A1 (da)
ZA (1) ZA201806849B (da)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL310508A (en) * 2016-04-19 2024-03-01 Intrabio Ltd Acetyl-leucine or its acceptable pharmacy salt for improved mobility and cognitive function
CN109789114A (zh) 2016-08-11 2019-05-21 内在生物技术有限公司 神经退行性疾病的治疗剂
GB201709459D0 (en) 2017-06-14 2017-07-26 Intrabio Ltd Treatment for migraine
US12145899B2 (en) 2018-12-06 2024-11-19 Intrabio Ltd. Deuterated analogs of acetyl-leucine
KR20210135272A (ko) * 2019-03-02 2021-11-12 인트라바이오 리미티드 질환을 치료하기 위한 류신, 아세틸 류신, 및 관련된 유사체
US12171852B1 (en) 2023-07-18 2024-12-24 Sytheon Ltd Composition and methods for regulating melanogenesis
WO2025166100A1 (en) 2024-02-02 2025-08-07 SynGAP Research Fund Compositions and methods for treating neurodevelopmental disorders

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060063827A1 (en) * 2004-09-23 2006-03-23 Yu Ruey J Systemic administration of therapeutic amino acids and N-acetylamino acids
US20070190070A1 (en) * 2004-09-03 2007-08-16 Zeldis Jerome B Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system
FR2883180B1 (fr) * 2005-03-18 2007-05-25 Pierre Fabre Medicament Sa Utilisation de l'acetyl-leucine pour la preparation d'un medicament destine au traitement de troubles de l'equilibre
FR2905600B1 (fr) * 2006-09-13 2010-01-15 Pf Medicament Traitement des vertiges par l'acetyl-l-leucine.
US20080097606A1 (en) * 2006-10-19 2008-04-24 Cragg Andrew H Knee joint prosthesis and hyaluronate compositions for treatment of osteoarthritis
WO2008134844A1 (en) * 2007-05-08 2008-11-13 Multi Formulations Ltd. Branched-chain amino acid composition for improving skeletal muscle protein metabolism
WO2011025518A1 (en) * 2009-08-27 2011-03-03 Albert Einstein College Of Medicine Of Yeshiva University Cognitive function training to improve motor ability
TN2010000251A1 (fr) * 2010-06-03 2011-11-11 Rekik Raouf N-acetyl-dl-leucine medicament neuro et retino protecteur
WO2012060844A1 (en) * 2010-11-05 2012-05-10 Biotie Therapies, Inc A2a antagonists as cognition and motor function enhancers
TN2010000566A1 (en) * 2010-12-03 2012-05-24 Rekik Raouf Folic acid - ramipril combination : cell protective neuroprotective and retinoprotective ophtalmologic drugs
IL310508A (en) * 2016-04-19 2024-03-01 Intrabio Ltd Acetyl-leucine or its acceptable pharmacy salt for improved mobility and cognitive function
WO2019079536A1 (en) * 2017-10-18 2019-04-25 Intrabio Ltd THERAPEUTIC AGENTS FOR IMPROVED MOBILITY AND COGNITIVE FUNCTION AND FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES AND LYSOSOMAL STORAGE DISORDERS

Also Published As

Publication number Publication date
JP2019513814A (ja) 2019-05-30
AU2022256077A1 (en) 2022-11-17
CN109069463A (zh) 2018-12-21
KR102791288B1 (ko) 2025-04-03
KR102632670B1 (ko) 2024-02-01
LT3445351T (lt) 2024-11-25
JP2022024058A (ja) 2022-02-08
MX388461B (es) 2025-03-20
FI3445351T3 (fi) 2024-11-18
ZA201806849B (en) 2019-07-31
HUE069219T2 (hu) 2025-02-28
MD3445351T2 (ro) 2024-12-31
US20250332133A1 (en) 2025-10-30
IL293266A (en) 2022-07-01
RS66142B1 (sr) 2024-12-31
US20230346732A1 (en) 2023-11-02
EP4501406A2 (en) 2025-02-05
KR20220038814A (ko) 2022-03-29
CN109069463B (zh) 2024-07-23
PL3445351T3 (pl) 2025-01-07
IL310508A (en) 2024-03-01
IL293266B2 (en) 2024-07-01
US12329733B2 (en) 2025-06-17
SMT202400459T1 (it) 2025-01-14
EP3445351A1 (en) 2019-02-27
RU2018140131A3 (da) 2020-05-14
AU2017252507B2 (en) 2022-07-21
SG11201809031XA (en) 2018-11-29
RU2018140131A (ru) 2020-05-14
IL262379B (en) 2022-07-01
RU2021107001A (ru) 2021-04-12
KR20240018683A (ko) 2024-02-13
KR102413754B1 (ko) 2022-06-27
KR20180134398A (ko) 2018-12-18
CA3021155A1 (en) 2017-10-26
NZ747307A (en) 2025-10-31
US20190083438A1 (en) 2019-03-21
CN118593463A (zh) 2024-09-06
HRP20241552T1 (hr) 2025-01-17
JP2024123087A (ja) 2024-09-10
AU2017252507A1 (en) 2018-11-08
MX2018012739A (es) 2019-06-17
PT3445351T (pt) 2024-11-14
IL262379A (en) 2018-11-29
RU2745912C2 (ru) 2021-04-02
SG10202106190RA (en) 2021-07-29
JP7506046B2 (ja) 2024-06-25
EP3445351B1 (en) 2024-10-16
KR20220093386A (ko) 2022-07-05
US10905670B2 (en) 2021-02-02
JP7387264B2 (ja) 2023-11-28
MX2021014844A (es) 2022-01-18
ES2994242T3 (en) 2025-02-05
EP4501406A3 (en) 2025-03-26
US20210106548A1 (en) 2021-04-15
SI3445351T1 (sl) 2025-04-30
US11998518B2 (en) 2024-06-04
IL293266B1 (en) 2024-03-01
WO2017182802A1 (en) 2017-10-26
BR112018071547A2 (pt) 2019-03-06

Similar Documents

Publication Publication Date Title
NO2025044I1 (no) Inavolisib or a pharmaceutically acceptable salt thereof
NO2025038I1 (no) Risdiplam or a pharmaceutically acceptable salt thereof - forlenget
FIC20240030I1 (fi) Danikopaani tai sen farmaseuttisesti hyväksyttävä suola
NO2022058I1 (no) Capmatinib or a pharmaceutically acceptable salt thereof
NL301111I2 (nl) Entrectinib of een farmaceutisch aanvaardbaar zout daarvan
IL284874A (en) Valbenazine salts and polymorphs thereof
IL282304A (en) Topical pharmaceutical compositions
NO2024009I1 (no) Gefapixant, or a pharmaceutically acceptable salt thereof
SI3529248T1 (sl) Farmacevtske spojine
LT3411541T (lt) Horizontalus klojinys
FIC20253004I1 (fi) Seladelpaari tai sen farmaseuttisesti hyväksyttävä suola, erityisesti seladelpaari-L-lysiinidihydraatti
DK3445351T3 (da) Acetyl-leucin eller et farmaceutisk acceptabelt salt deraf til forbedret mobilitet
DK3529240T3 (da) Farmaceutiske forbindelser
DK3558961T3 (da) Polymorfer
DK3558995T3 (da) Polymorfer
DK3463345T3 (da) Farmaceutiske kombinationer
NO2024058I1 (no) delgocitinib or a pharmaceutically acceptable salt thereof
EP3437644A4 (en) MEDICINE
DK3560925T3 (da) Hidtil ukendt forbindelse og farmaceutisk acceptabelt salt deraf
DK3445742T3 (da) Krystallin tapentadolphosphat
PL3206672T3 (pl) Preparaty o przedłużonym uwalnianiu środków znieczulających miejscowo
EP3527216A4 (en) Medicine
DK3728220T3 (da) Farmaceutiske forbindelser
DK3288967T3 (da) Farmaceutisk forbindelse
DK3412667T3 (da) Cokrystal